Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

Rose, Peter G.; Blessing, John A.; Gershenson, David M.; McGehee, Ramon

doi:10.1200/jco.1999.17.9.2676

Cited by 195 publications

(106 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several combination chemotherapy regimens that contain cisplatin have been tested in phase II studies, and objective responses have been documented in 30 -70% of the patients, while the median overall survival time ranged between 7 and 12 months (Buxton et al, 1989;Murad et al, 1994;Long et al, 1995;Papadimitriou et al, 1997Papadimitriou et al, , 1999Rose et al, 1999). Although it is difficult to directly compare the relative merits of the combined regimens with the single agents, combination chemotherapy seems to be superior to single-agent therapy based on these phase II studies.…”

Section: Discussionmentioning

confidence: 99%

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer

Tsuda

Hashiguchi

Nishimura³

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

Combination chemotherapy with irinotecan (CPT-11) and platinum compounds is effective for treating cervical cancer. Nedaplatin (254-S) is a new cisplatin analogue that achieves a high response rate (53%) in patients with primary cervical cancer. We performed a phase I -II study of combination chemotherapy with CPT-11 plus 254-S for advanced or recurrent cervical cancer. The inclusion criteria were stage IV disease or recurrence. CPT-11 and 254-S were administered intravenously on day 1, while rhG-CSF (50 mg) was given on days 3 -12. This regimen was repeated after 4 weeks. Dose escalation was carried out in tandem (CPT-11/254-S: 50/70, 50/80, and 60/80 mg m À2 ). A total of 27 patients (stage IV ¼ seven, recurrence ¼ 20) were enrolled. The phase I study enrolled eight patients. At dose levels 1 and 2, no dose-limiting toxicities were observed. At dose level 3, the first two patients developed DLTs. The maximum tolerated dose of CPT-11 and 254-S was 60 and 80 mg m À2 , respectively, and the recommended doses were 50 and 80 mg m À2 . Grade 3/4 haematologic toxicity occurred in 67% in phase II study, but there were no grade 3 nonhaematologic toxicities except fot nausea or lethargy. In all 27 patients, there were two complete responses (7%) and 14 Partial responses (52%), for an overall response rate of 59% (95% confidence interval: 39 -78%). Among the 12 responders with recurrent disease, the median time to progression and median survival were 161 days (range: 61 -711 days) and 415 days (range: 74 -801 days). This new regimen is promising for cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer

Tsuda

Hashiguchi

Nishimura³

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…To this day, these limited-access trials follow a two-stage accrual methodology, and those that have been completed or are currently accruing patients appear in Table 1 [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. Because these studies compete with phase III trials, they are open only at a small number of sites.…”

Section: The 76 Series and Other Phase II Studiesmentioning

confidence: 99%

“…Single agents tested in this series with decent performance include ifosfamide (GOG-76I, overall response rate 15.7%) [19], paclitaxel (GOG-76S, overall response rate 17.3%) [24], topotecan (GOG-76U, overall response rate 18.6%) [26], and dibromodulcitol (GOG-76D, overall response rate 29%) [15]. Promising combinations include cisplatin and vinorelbine (GOG-76Z, overall response rate 30%) [30], and cisplatin and paclitaxel (GOG-76X, overall response rate 46.3%) [28].…”

Section: The 76 Series and Other Phase II Studiesmentioning

confidence: 99%

“…In protocol 76S, the GOG had reported a 17% overall response rate for single-agent paclitaxel in advanced squamous cell carcinoma of the cervix [24], and when combined with cisplatin as part of a feasibility study (GOG-76X) [28], an impressive overall objective response rate of 46.3% had been documented (Table 1).…”

Section: Cisplatin Versus Cisplatin-based Combinations: Response Ratementioning

confidence: 99%

See 1 more Smart Citation

Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer

Tewari

Monk

2005

Curr Oncol Rep

View full text Add to dashboard Cite

“…This highlights the requirement for additional agents in the treatment and management of human cancer. In recent years, combination regimens involving cisplatin and microtubule-disrupting agents have been explored, and initial results demonstrate improved response rates over single therapy regimens (Rose et al, 1999;Sawada et al, 2003).…”

mentioning

confidence: 99%

Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo

et al. 2007

View full text Add to dashboard Cite

Titanocene compounds are a novel series of agents that exhibit cytotoxic effects in a variety of human cancer cells in vitro and in vivo. In this study, the antiproliferative activity of two titanocenes (Titanocenes X and Y) was evaluated in human epidermoid cancer cells in vitro. Titanocenes X and Y induce apoptotic cell death in epidermoid cancer cells, with IC50 values that are comparable to cisplatin. Characterisation of the cell death pathway induced by titanocene compounds in A431 cells revealed that apoptosis is preceded by cell cycle arrest and the inhibition of cell proliferation. The induction of apoptosis is dependent on the activation of caspase-3 and -7 but not caspase-8. Furthermore, the antitumour activity of Titanocene Y was tested in an A431 xenograft model of epidermoid cancer. Results indicate that Titanocene Y significantly reduced the growth of A431 xenografts with an antitumour effect similar to cisplatin. These results suggest that titanocenes represent a novel series of promising antitumour agents.

show abstract

Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

Abstract: This regimen seems highly active in advanced and recurrent squamous cell carcinoma of the cervix and is currently being evaluated by the GOG in a phase III randomized study comparing the combination of paclitaxel and cisplatin with cisplatin alone.

Cited by 195 publications

References 17 publications

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer

Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer

Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo

Contact Info

Product

Resources

About